Printer Friendly

New Study Showed Keppra(R) in Combination with Conventional Treatments Provided Pain Relief in Multiple Sclerosis Patients.

CHICAGO and SMYRNA, Ga. -- CHICAGO and SMYRNA, Ga., March 20 /PRNewswire/ -- Results from a new study showed that the antiepileptic drug Keppra(R) (levetiracetam), in combination with tricyclic antidepressants, anticonvulsant drugs and/or long-acting narcotics, provided some multiple sclerosis (MS) patients improvement in pain and uncomfortable sensations associated with their condition. The study of Keppra(R), which is approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults with epilepsy, was conducted at the MS Treatment and Research Center of the Yale School of Medicine and presented today at the American Pain Society's 22nd Annual Scientific Meeting.

MS affects more than 400,000 people in North America and about 2.5 million worldwide(1). Over 60 percent of MS patients experience moderate to severe pain, although less than 10 percent are on medication(2). Frequent syndromes encountered include painful limb spasms; deep, aching leg pain; a burning sensation and uncomfortable buzzing sensations derived from spinal cord involvement.

"We were interested in studying Keppra(R) in combination with more commonly used treatments for neuropathic pain and paresthesias in MS patients. Because of its unique mechanism of action, it can potentially complement other anticonvulsant treatments," said Marco Rizzo, M.D., Ph.D., author of the study and assistant professor at the Yale School of Medicine, New Haven, Conn. "We were impressed to find that Keppra(R) was well-tolerated and effective for neuropathic pain and uncomfortable numbness."

In this open-label study, Keppra(R) was given to 21 MS patients who continued to have disabling neuropathic symptoms despite more conventional treatments. More than half of the patients showed marked improvement and continue to be treated with Keppra(R). In combination with tricyclic compounds, other anticonvulsants, and/or long-acting narcotics, the dose was titrated up to between 500 and 4,500 mg/day.

More than half (12 of 21) of patients exhibited moderate to marked improvement of symptoms as a result of the introduction of Keppra(R) therapy. Three of the 21 patients showed mild improvement; five showed no positive response and one patient discontinued at 500 mg/day due to fatigue and disorientation. Two of the 12 patients who showed moderate or marked symptom improvement were able to discontinue all other pain therapies after treatment for 4 to 8 months. A majority of the patients remain on adjunctive Keppra(R) treatment today.

Adverse events that could not with confidence be correlated directly with Keppra(R) use included weakness, urinary retention, worsening spasticity and numbness.

Keppra(R) use is associated with the occurrence of central nervous system adverse events, including somnolence and fatigue, coordination difficulties, and behavioral abnormalities, and with minor, but statistically significant, hematological abnormalities. Keppra(R) dosing must be individualized according to renal function status.

UCB Pharma, Inc., with U.S. headquarters in Smyrna, Ga., is the North American subsidiary of the global, research-based pharmaceutical sector of UCB S.A. The pharmaceutical sector is dedicated to the development and commercialization of innovative pharmaceutical products for the treatment of neurological diseases and allergy-asthma. UCB S.A. has core businesses in pharmaceuticals and surface specialties, and employs over 10,000 people globally in more than 100 countries. Worldwide headquarters are located in Brussels, Belgium.
 For full prescribing information consult www.keppra.com .
 (1) The National Multiple Sclerosis Society www.nationalmssociety.org
 (Last accessed 3/6/03)
 (2) Ni, W. "Pain Syndromes in MS: Severity, Impact on Quality of Life,
 and Treatment Patterns." Presented at 53rd Annual Meeting of the
 American Academy of Neurology, May 5-11, 2001. www.aan.com


CONTACT: Lisa Garman of UCB Pharma, Inc., cell, +1-404-291-4772, or lisa.garman@ucb-group.com; Jessica Balaban of Ketchum, +1-646-935-4054, or jessica.balaban@ketchum.com

Web site: http://www.keppra.com/ http://www.nationalmssociety.org/ http://www.aan.com/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 20, 2003
Words:631
Previous Article:Bush Administration Authorizes Humanitarian Food Assistance for Citizens of Iraq.
Next Article:Arlington Park to Distribute Breeders' Cup Ultra Pick 6 Winnings; Resolution of Criminal Case Leads to Release of Winning Monies to Rightful Owners.


Related Articles
New Data [1] demonstrate KEPPRA offers sustained efficacy, reduction in seizure frequency and in concomitant medication.
New Data(1) Demonstrate KEPPRA(R)* Offers Sustained Efficacy, Reduction in Seizure Frequency and in Concomitant Medication; KEPPRA's Place at the...
Epilepsy Drug Keppra(R) Now Approved in Oral Solution.
New study (Reference 1) demonstrates that KEPPRA (levetiracetam) significantly increases the number of seizure free days for patients with refractory...
Dr Miriam Stoppard's Health Focus Today: CANNABIS - THE PROS AND CONS - Why weed is still a worry.
FDA Approves Keppra(R) as Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy.
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R).
Video: Keppra XR(TM) Approved in the U.S.
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures.
New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters